Predix Pharmaceuticals Achieves Full Enrollment For Phase III Clinical Trial Of PRX-00023 In Generalized Anxiety Disorder

LEXINGTON, Mass. & RAMAT GAN, Israel--(BUSINESS WIRE)--May 24, 2006--Predix Pharmaceuticals Holdings, Inc., which recently announced a definitive agreement to merge with EPIX Pharmaceuticals, Inc. (Nasdaq: EPIX - News), announced today that it has completed enrollment for its first Phase III trial of PRX-00023, the company's novel, long-acting 5-HT1A agonist, in patients with generalized anxiety disorder (GAD). This trial is the first of at least two pivotal trials expected in GAD.